ClinicalTrials.gg
CompletedNCT06998056Updated Dec 10, 2025

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

A Phase 2 interventional study of ARQ-151 cream 0.05% in Atopic Dermatitis (Eczema), sponsored by Arcutis Biotherapeutics, Inc.. Completed at 22 sites in 3 countries. Open to participants aged 3 Months to 2 Years. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
3 Months to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.

Enrollment
8th of 13
101 · median 136
Started
2025
with 1 other
Phase 2
4 of 13
1 open now
Registered
9th of 13
by date
Lead sponsor
8 of 13
Arcutis Biotherapeutics, Inc.

Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 3 Months to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing roflumilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).

Read the detailed description

This study is an open label safety study in which ARQ-151 cream 0.05% is applied once a day for 4 weeks in infants with atopic dermatitis (eczema).

03

Conditions studied

  • Atopic Dermatitis (Eczema)

Keywords

  • atopic dermatitis
  • eczema
04

Who can participate

Ages eligible
3 Months to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. of a parent(s) or legal guardian(s), as required by local laws.
  2. Males and females, ages 3 months to \<2 years old at Day 1.
  3. Diagnosed with mild to moderate Atopic Dermatitis (AD) for at least 1 month duration prior to or at the screening visit.
  4. Has AD involvement of ≥3% BSA at Day1.
  5. In good health as judged by the Investigator
  6. Subjects and parent(s)/legal guardian(s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any serious medical condition, vital signs, or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
  2. Subjects who have unstable AD or any consistent requirement for high potency topical to manage AD signs or symptoms.
  3. Subjects previously treated with ARQ-151
  4. Subjects currently undergoing allergy testing or food challenges, or plan to do so during the study.
  5. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language. Subjects who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
  6. Subjects who are family members of the clinical study staff or sponsor.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    ARQ-151 roflumilast cream 0.05% (open label)

    This single study arm is open label in which ARQ-151 cream 0.05% is applied daily for 4 weeks.

    Drug: ARQ-151 cream 0.05%

Interventions

  • ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).

06

What researchers measure

Primary outcomes

  1. Subject incidence of adverse events

    Number of participants with adverse events during treatment will be assessed

    Time frame: 4 weeks

  2. Subject incidence of serious adverse events

    Number of participants with serious adverse events during treatment will be assessed

    Time frame: 4 weeks

  3. Incidence of application site reactions

    Number of subjects that experience an application site skin reaction by investigator assessment and application site reactions reported as adverse events will be assessed

    Time frame: 4 weeks

07

Study locations

22 sites
  • Arcutis Clinical Study Site 208
    Birmingham, Alabama 35244, United States
  • Arcutis Clinical Study Site 221
    Bryant, Arkansas 72022, United States
  • Arcutis Clinical Study Site 214
    Fountain Valley, California 92708, United States
  • Arcutis Clinical Study Site 209
    Rancho Santa Margarita, California 92688, United States
  • Arcutis Clinical Study Site 207
    Coral Gables, Florida 33146, United States
  • Arcutis Clinical Study Site 217
    Delray Beach, Florida 33484, United States
  • Arcutis Clinical Study Site 213
    Jacksonville, Florida 32256, United States
  • Arcutis Clinical Study Site 223
    Boise, Idaho 83706, United States
  • Arcutis Clinical Study Site 219
    West Lafayette, Indiana 47906, United States
  • Arcutis Clinical Study Site 212
    Minneapolis, Minnesota 55112, United States
  • Arcutis Clinical Study Site 211
    Portsmouth, New Hampshire 03801, United States
  • Arcutis Clinical Study Site 220
    Mason, Ohio 45040, United States
  • Arcutis Clinical Study Site 206
    Portland, Oregon 97239, United States
  • Arcutis Clinical Study Site 222
    Summerville, South Carolina 29486, United States
  • Arcutis Clinical Study Site 210
    Bellaire, Texas 77401, United States
  • Arcutis Clinical Study Site 224
    Fort Worth, Texas 76244, United States
  • Arcutis Clinical Study Site 202
    San Antonio, Texas 78218, United States
  • Arcutis Clinical Study Site 203
    Winnipeg, Manitoba R3J0S9, Canada
  • Arcutis Clinical Study Site 204
    Halifax, Nova Scotia B3K 5R3, Canada
  • Arcutis Clinical Study Site 216
    Waterloo, Ontario N2J1C4, Canada
  • Arcutis Clinical Study Site 225
    Saskatoon, Saskatchewan S7K2C1, Canada
  • Arcutis Clinical Study Site 201
    Santo Domingo, 10306, Dominican Republic
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Dec 2025, 5 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 5 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
May 31, 2025
StartActual
Jun 9, 2025
Primary completionActual
Dec 4, 2025
CompletionActual
Dec 4, 2025
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06998056
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Jun 9, 2025
Primary completion
Dec 4, 2025
Completion
Dec 4, 2025
Last update
Dec 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion